Peptides · Peptide comparison
Pramlintide vs Semaglutide
Synthetic amylin analog for comprehensive postprandial glucose control with insulin therapy
The revolutionary once-weekly GLP-1 medication that helps your body feel full faster and longer, leading to significant weight loss while also protecting your heart—FDA approved and backed by some of the largest clinical trials in obesity medicine history.
- Weight Management
- Weight Management
At a glance
Quick comparison
Efficacy
Benefit ratings
Blood Sugar Control
Weight Management
Metabolic Health
Weight Loss
Appetite Control
Heart Protection
Technical data
Compound specifications
Pramlintide
- Molecular formula
- C171H267N51O53S2
- Molecular weight
- 3,949 Da
- Half-life
- ~48 minutes
- Bioavailability
- 30-40% subcutaneous bioavailability
- CAS number
- 196078-30-5
Semaglutide
- Molecular formula
- C187H291N45O59
- Molecular weight
- 4113.58 g/mol
- Half-life
- Approximately 7 days (168 hours)
- Bioavailability
- 89% (subcutaneous); 0.4-1% (oral, with absorption enhancer)
- CAS number
- 910463-68-2
Protocols
Dosing compared
Pramlintide
Subcutaneous
- Titrate up after 3+ days without significant nausea15 mcg per meal (type 1 diabetes)Immediately before each major meal · Titrate up after 3+ days without significant nauseaFDA Symlin label starting dose for type 1 diabetes. Inject before each major meal (>=250 kcal or >=30 g carbohydrate); reduce mealtime insulin by 50% when starting. [6]
- Ongoing, as tolerated30-60 mcg per meal (type 1 diabetes)Immediately before each major meal · Ongoing, as toleratedType 1 maintenance target per FDA label: titrate 15 -> 30 -> 45 -> 60 mcg, stepping up each time no significant nausea occurs for 3+ days; settle at 30 or 60 mcg as tolerated. [6]
- Increase to 120 mcg after 3+ days without significant nausea60 mcg per meal, titrating to 120 mcg (type 2 diabetes)Immediately before each major meal · Increase to 120 mcg after 3+ days without significant nauseaFDA Symlin label for type 2 diabetes: start 60 mcg, advance to 120 mcg maintenance as tolerated. Separate injection from insulin; cut mealtime insulin 50% at start. [6]
Semaglutide
Subcutaneous
- 4 weeks0.25 mgOnce weekly · 4 weeksThis is the starter dose to help your body adjust. It does not lower blood sugar much on its own, so it is only used for the first 4 weeks before stepping up [5].
- At least 4 weeks at each step0.5-1 mgOnce weekly · At least 4 weeks at each stepAfter the starter month, the dose goes up to 0.5 mg, and can rise to 1 mg if more blood sugar control is needed. Wait at least 4 weeks before each increase [5].
- Ongoing/maintenance2-2.4 mgOnce weekly · Ongoing/maintenanceThe highest weekly doses. 2 mg is the maximum for diabetes (Ozempic) [5]; up to 2.4 mg is used for weight management (Wegovy) after a slower titration.
Oral
- 30 days3 mgOnce daily · 30 daysThe pill form (Rybelsus) starts at 3 mg each morning for 30 days. Like the starter shot, this dose is for getting started and does not control blood sugar by itself. Take on an empty stomach with a small sip of water, 30 minutes before food or other pills [6].
- 30+ days7 mgOnce daily · 30+ daysAfter the first 30 days, the dose increases to 7 mg once daily. This is the first dose that actively lowers blood sugar [6].
- Ongoing/maintenance14 mgOnce daily · Ongoing/maintenanceThe highest pill dose, used if more blood sugar control is needed after at least 30 days at 7 mg [6].
Applications
Best suited for
Pramlintide
- Improving postprandial glucose control in insulin-treated diabetes
- Pramlintide is particularly well-suited for individuals focused on improving postprandial glucose control in insulin-treated diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3][6].
- Reducing insulin dose requirements while maintaining glycemic control
- Pramlintide is particularly well-suited for individuals focused on reducing insulin dose requirements while maintaining glycemic control. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3].
- Supporting weight management in insulin-treated T1DM and T2DM patients
- Pramlintide is particularly well-suited for individuals focused on supporting weight management in insulin-treated t1dm and t2dm patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [6].
- Addressing amylin deficiency in insulin-dependent diabetes
- Pramlintide is particularly well-suited for individuals focused on addressing amylin deficiency in insulin-dependent diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
Semaglutide
- People with Obesity Seeking Significant Weight Loss
- If your BMI is 30 or higher (or 27+ with weight-related health conditions), semaglutide is currently one of the most effective non-surgical weight loss options available. [7] Clinical trials show average weight loss of 15% of body weight—that's 30+ pounds for someone starting at 200 pounds [1].
- Those Who've Struggled with Diet and Exercise Alone
- Semaglutide works by changing the biological signals that drive hunger and cravings. If you've tried to lose weight through willpower alone and found yourself constantly battling hunger, this medication addresses that underlying biology rather than just telling you to eat less [3][7][13].
- People with Type 2 Diabetes Needing Better Control
- Originally developed for diabetes, semaglutide excellently controls blood sugar while also promoting weight loss—addressing two major health concerns simultaneously. [3][5] It can often allow people to reduce or eliminate other diabetes medications [21].
- Individuals at High Cardiovascular Risk
- The SELECT trial proved that semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% in people with obesity and existing heart disease—even without diabetes. It's one of the few weight loss medications proven to improve hard cardiovascular outcomes [2].
Safety profile
Side effects
Pramlintide
Common
- Nausea
- Reduced Appetite / Anorexia
- Headache
Uncommon
- Abdominal Pain and Vomiting
- Injection Site Reactions
Serious
- Severe Hypoglycemia (BLACK BOX WARNING)
Semaglutide
Common
- Nausea
- Constipation or Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Loss (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Research status
Safety & evidence
Pramlintide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- FDA-approved pramlintide demonstrates good tolerability in insulin-treated diabetes with well-characterized safety profile from >20 years clinical use. Gastrointestinal side effects (nausea) occur in 30-50% of initiators but typically resolve within 1-3 weeks. Hypoglycemia risk, especially when combined with insulin, requires dose coordination and patient education. [6] Pancreatic side effects theoretically possible but not documented in clinical trials. Pregnancy category C requires careful consideration.
Contraindications
- Confirmed gastroparesis [6] requiring treatment
- Hypoglycemia unawareness (inability to recognize hypoglycemic symptoms) [6]
- Known hypersensitivity to pramlintide or metacresol [6]
- Pediatric patients (safety not established in children) [6]
Semaglutide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Semaglutide has been studied in over 20,000 participants across multiple large clinical trials, making it one of the most thoroughly researched weight loss medications available. [1][2][8][9][10] The FDA approved it after rigorous review of safety data. While GI side effects are common (especially early on), serious side effects are rare. [1][7] The SELECT trial showed it actually reduces cardiovascular events, adding a safety benefit beyond just weight loss [2].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) [7]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [7]
- History of serious allergic reaction to semaglutide [7]
Decision guide
Which is right for you?
Pramlintide
Choose Pramlintide if…
- Improving postprandial glucose control in insulin-treated diabetes
- Reducing insulin dose requirements while maintaining glycemic control
- Supporting weight management in insulin-treated T1DM and T2DM patients
- Addressing amylin deficiency in insulin-dependent diabetes
Semaglutide
Choose Semaglutide if…
- Significant weight loss
- Long-term weight management
- Cardiovascular risk reduction
- Blood sugar control